MITO
Income statement / Annual
Last year (2021), Stealth BioTherapeutics Corp's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2021, Stealth BioTherapeutics Corp's net income was -$53.77 M.
See Stealth BioTherapeutics Corp,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$21.09 M |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$21.09 M
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
1
|
0
|
0
|
0
|
| Research and Development Expenses |
$26.56 M
|
$29.31 M
|
$44.60 M
|
$53.06 M
|
$63.22 M
|
$48.45 M
|
| General & Administrative Expenses |
$19.75 M
|
$19.37 M
|
$22.32 M
|
$22.22 M
|
$16.50 M
|
$13.40 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$19.75 M
|
$19.37 M
|
$22.32 M
|
$22.22 M
|
$16.50 M
|
$13.40 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$46.30 M
|
$48.67 M
|
$66.92 M
|
$75.28 M
|
$79.72 M
|
$61.85 M
|
| Cost And Expenses |
$46.30 M
|
$48.67 M
|
$66.92 M
|
$75.28 M
|
$79.72 M
|
$61.85 M
|
| Interest Income |
$3,000.00
|
$139,000.00
|
$988,000.00
|
$195,087.00
|
$56,843.00
|
$799,023.00
|
| Interest Expense |
$1.24 M
|
$1.81 M
|
$6.67 M
|
$21.36 M
|
$3.28 M
|
$0.00
|
| Depreciation & Amortization |
$77,000.00
|
$232,000.00
|
$284,000.00
|
$309,041.00
|
$346,872.00
|
$312,537.00
|
| EBITDA |
-$51.21 M |
-$55.42 M |
-$64.78 M |
-$75.05 M |
-$79.28 M |
-$60.74 M |
| EBITDA Ratio |
0
|
0
|
-3.07
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
-2.17
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$6.22 M
|
-$8.79 M
|
-$25.90 M
|
-$21.43 M
|
-$3.19 M
|
$799,023.00
|
| Income Before Tax |
-$52.53 M
|
-$57.46 M
|
-$71.73 M
|
-$96.71 M
|
-$82.91 M
|
-$61.05 M
|
| Income Before Tax Ratio |
0
|
0
|
-3.4
|
0
|
0
|
0
|
| Income Tax Expense |
$1.24 M
|
-$6.98 M
|
-$19.23 M
|
-$76,213.00
|
$92,300.00
|
$799,023.00
|
| Net Income |
-$53.77 M
|
-$57.46 M
|
-$71.73 M
|
-$96.71 M
|
-$82.91 M
|
-$61.05 M
|
| Net Income Ratio |
0
|
0
|
-3.4
|
0
|
0
|
0
|
| EPS |
-1.16 |
-1.24 |
-2.29 |
-2.93 |
-5.22 |
-2.99 |
| EPS Diluted |
-1.16 |
-1.24 |
-2.29 |
-2.93 |
-5.22 |
-2.99 |
| Weighted Average Shares Out |
$46.35 M
|
$46.35 M
|
$31.31 M
|
$33.02 M
|
$15.88 M
|
$20.38 M
|
| Weighted Average Shares Out Diluted |
$46.35 M
|
$46.35 M
|
$31.31 M
|
$33.02 M
|
$15.88 M
|
$20.38 M
|
| Link |
|
|
|
|
|
|
